Management acknowledged potential generic competition for VIVITROL in 2027, noting the product's manufacturing complexity as a significant barrier to entry for competitors.The expiration of Zeppelin royalties in the second half of 2026 is expected to create a headwind for manufacturing and royalty revenue streams.VIVITROL and ARISTADA 2025 results included $27M and $14M respectively in one-time gross-to-net favorability that management explicitly stated will not recur in 2026.A non-cash inventory step-up ch ...